A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs BAY 1093884 (Primary) ; BAY 1093884 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 09 Mar 2018 Planned End Date changed from 31 Jul 2018 to 6 Aug 2018.
- 09 Mar 2018 Planned primary completion date changed from 15 Jun 2018 to 25 Jun 2018.
- 09 Jan 2018 Planned number of patients changed from 38 to 32.